Filing Flows › Pelthos Therapeutics (PTHS) › Q2 2026
Pelthos Therapeutics (PTHS) Q2 2026 earnings results (second quarter 2026)
10-Q filed Aug 13, 2026
Pelthos Therapeutics (PTHS) reported revenue of $15.6M for the second quarter 2026 (Q2 2026) and +43% from the quarter before. Operating margin was -111.0%, net loss $23.4M (150.1% of revenue).
Pelthos Therapeutics, Q2 2026: revenue $15.6M, operating margin -111.0%, net loss $23.4M, operating cash flow −$7.7M. The chart follows the revenue to costs, profit and cash.
| Q2 2026 | Amount | Q/Q | Y/Y |
|---|---|---|---|
| Revenue | $15.6M | +43% | — |
| Operating profit | −$17.3M | — | — |
| Net earnings | −$23.4M | — | — |
| Operating cash flow | −$7.7M | — | — |
What changed
Revenue was $15.6M in Q2 2026, up 43% from the previous quarter. Net product revenues was the largest line at 99% of revenue.
Operating costs exceeded revenue by $17.3M, an operating margin of -111.0%. The quarter ended with a net loss of $23.4M, narrower than the previous quarter's $25.1M loss.
Operating cash flow was −$7.7M. Non-cash charges added back $1.3M of depreciation and amortization and $2.8M of share-based compensation. Working capital and other items added $11.7M. Capital expenditures of $2K exceeded it, leaving free cash flow of −$7.7M.
Questions
What was Pelthos Therapeutics' revenue in the second quarter 2026?
Pelthos Therapeutics (PTHS) reported revenue of $15.6M for the second quarter 2026 (Q2 2026) and +43% from the quarter before.
Was Pelthos Therapeutics profitable in the second quarter 2026?
Operating loss was $17.3M (-111.0% of revenue) and net loss $23.4M.